- Home
- EVG vs MNOV Comparison
EVG vs MNOV Comparison
Compare EVG & MNOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
EVG
Eaton Vance Short Diversified Income Fund Eaton Vance Short Duration Diversified Income Fund of Beneficial Interest
Current Price
Company Overview
Basic Information| Metric | EVG | MNOV |
|---|---|---|
| Founded | N/A | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.9M | 137.8M |
| IPO Year | 2004 | 2004 |
Fundamental Metrics
Financial Performance| Metric | EVG | MNOV |
|---|---|---|
| Price | $10.34 | $1.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.25 |
| AVG Volume (30 Days) | 52.6K | ★ 56.3K |
| Earning Date | 01-01-0001 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,360,807.00 |
| Revenue This Year | N/A | $78.20 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 194.15 |
| 52 Week Low | $9.78 | $1.22 |
| 52 Week High | $11.30 | $3.90 |
Technical Indicators
Market Signals| Indicator | EVG | MNOV |
|---|---|---|
| Relative Strength Index (RSI) | 51.43 | 44.45 |
| Support Level | $9.99 | $1.28 |
| Resistance Level | $10.95 | $1.54 |
| Average True Range (ATR) | 0.19 | 0.06 |
| MACD | -0.00 | 0.03 |
| Stochastic Oscillator | 55.92 | 59.70 |
Price Performance
Historical ComparisonAbout EVG Eaton Vance Short Diversified Income Fund Eaton Vance Short Duration Diversified Income Fund of Beneficial Interest
Eaton Vance Short Duration Diversified Income Fund is a diversified, closed-end management investment company. Its primary investment objective is to provide a high level of current income with a secondary objective of seeking capital appreciation to the extent consistent with its primary goal. The portfolio of investments consists of business equipment and services, automotive, cable and satellite television, chemicals and plastics, food products, and other areas.
About MNOV Medicinova Inc
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.